Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 May 21;64(6):e00290-20.
doi: 10.1128/AAC.00290-20. Print 2020 May 21.

In Vitro and In Vivo Study on the Synergistic Effect of Minocycline and Azoles against Pathogenic Fungi

Affiliations

In Vitro and In Vivo Study on the Synergistic Effect of Minocycline and Azoles against Pathogenic Fungi

Lujuan Gao et al. Antimicrob Agents Chemother. .

Abstract

In vitro and in vivo interactions of minocycline and azoles, including itraconazole, voriconazole, and posaconazole, against filamentous pathogenic fungi were investigated. A total of 56 clinical isolates were studied in vitro via broth microdilution checkerboard technique, including 20 strains of Aspergillus fumigatus, 7 strains of Aspergillus flavus, 16 strains of Exophiala dermatitidis, 10 strains of Fusarium solani, and 3 strain s of Fusarium oxysporum The results revealed that minocycline did not exhibit any significant antifungal activity against any of the tested strains. However, favorable synergy of minocycline with itraconazole, voriconazole, or posaconazole was observed against 34 (61%), 28 (50%), and 38 (68%) isolates, respectively, including azole-resistant A. fumigatus and Fusarium spp. with inherently high MICs of azoles. Synergistic combinations resulted in 4-fold to 16-fold reduction of effective MICs of minocycline and azoles. No antagonism was observed. In vivo effects of minocycline-azole combinations were evaluated by survival assay in a Galleria mellonella model infected with E. dermatitidis strain BMU00034; F. solani strain FS9; and A. fumigatus strains AF293, AFR1, and AFR2. Minocycline acted synergistically with azoles and significantly increased larvae survival in all isolates (P < 0.001), including azole-resistant A. fumigatus and azole-inactive Fusarium spp. In conclusion, the results suggested that minocycline combined with azoles may help to enhance the antifungal susceptibilities of azoles against pathogenic fungi and had the potential to overcome azole resistance issues.

Keywords: Aspergillus; Exophiala; Fusarium; antifungal; azole; fungi; minocycline; resistance; synergy; tetracycline.

PubMed Disclaimer

Figures

FIG 1
FIG 1
Survival curve of G. mellonella infected with A. fumigatus. (A) AF293, (B) AFR1, (C) AFR2. ****, P < 0.0001; ***, P < 0.001; **, P < 0.01; *, P < 0.05.
FIG 2
FIG 2
Survival curve of G. mellonella infected with E. dermatitidis (A) and F. solani (B). ****, P < 0.0001; ***, P < 0.001; **, P < 0.01; *, P < 0.05.

References

    1. Kontoyiannis DP, Bodey GP. 2002. Invasive aspergillosis in 2002: an update. Eur J Clin Microbiol Infect Dis 21:161–172. doi:10.1007/s10096-002-0699-z. - DOI - PubMed
    1. Steinbach WJ, Marr KA, Anaissie EJ, Azie N, Quan SP, Meier-Kriesche HU, Apewokin S, Horn DL. 2012. Clinical epidemiology of 960 patients with invasive aspergillosis from the PATH Alliance registry. J Infect 65:453–464. doi:10.1016/j.jinf.2012.08.003. - DOI - PubMed
    1. Guarro J. 2013. Fusariosis, a complex infection caused by a high diversity of fungal species refractory to treatment. Eur J Clin Microbiol Infect Dis 32:1491–1500. doi:10.1007/s10096-013-1924-7. - DOI - PubMed
    1. Li DM, Li RY, de Hoog GS, Sudhadham M, Wang DL. 2011. Fatal Exophiala infections in China, with a report of seven cases. Mycoses 54:e136–e142. doi:10.1111/j.1439-0507.2010.01859.x. - DOI - PubMed
    1. Hagiya H, Maeda T, Kusakabe S, Kawasaki K, Hori Y, Kimura K, Ueda A, Yoshioka N, Sunada A, Nishi I, Morii E, Kanakura Y, Tomono K. 2019. A fatal case of Exophiala dermatitidis disseminated infection in an allogenic hematopoietic stem cell transplant recipient during micafungin therapy. J Infect Chemother 25:463–466. doi:10.1016/j.jiac.2018.12.009. - DOI - PubMed

Publication types

LinkOut - more resources